Major US hospital-based clinical trial highlights benefit of nasal decolonization to reduce ICU infections caused by Staphylococcus aureus
Destiny Pharma PLC (DEST.L) Study gives strong support for potential of XF-73 & CEO Interview
Traders Cafe with Zak Mir: THG, ORPH, ORCP, BOOM, DEV, ASLR, HEMO, QTZ, THR, BHL, CRCL, DEFI, HGEN, RENE, DEST & CCZ
It may be that after today’s announcement that bears of THG (THG) feel that they may be on the wrong side of the price action. The company said CEO Matthew
Share Talk Bulletin Board Heroes, Monday 29th March 2021
Zak Mir highlights some of the most followed stocks on the small-cap London market and gives an overview in this video charting update.
Destiny Pharma PLC (DEST.L) to Join Equity Development Webinar
Destiny Pharma to Join Equity Development Webinar on Positive Phase 2b Top-line Results for XF-73 Nasal Gel
Weekend Edition, Bulletin Board Heroes, Sunday 17th January 2021
Zak Mir highlights some of the most followed stocks on the small-cap London market and gives an overview in this video charting update.
Share Talk Bulletin Board Heroes, Friday 23rd October 2020
Zak Mir highlights some of the most followed stocks on the small-cap London market and gives an overview of the fundamentals in this video charting update.
Stock Market Watch: AMC, BZT, XTR, N4P, TOOP, FCCN, DEST & INX
Stocks that may or may not make the grade in the papers
Share Talk Bulletin Board Heroes, Tuesday 6th October 2020
Zak Mir highlights some of the most followed stocks on the small-cap London market and gives an overview of the fundamentals in this video charting update.
Share Talk Bulletin Board Heroes, Tuesday 4th August 2020
Zak Mir highlights some of the most followed stocks on the small-cap London market and gives an overview of the fundamentals in this video charting update.
Destiny Pharma (AIM:DEST) Development and commercial agreement finalised
Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel anti-microbial drugs, which address the global problem of anti-microbial resistance (AMR), announces that the outline
Destiny Pharma IPOs on to AIM and announces Chinese collaboration
Destiny Pharma, a clinical stage biotechnology company focused on the development of novel anti-microbial drugs, which address the global problem of anti-microbial resistance (AMR), is pleased to announce the admission
